1. Kingdon J, Roscamp J, Sangle S, D’Cruz D. Relapsing polychondritis: a clinical review for rheumatologists. Rheumatol Oxf Engl. 2018 Sep 1;57(9):1525–32.
2. Rednic S, Damian L, Talarico R, Scirè CA, Tobias A, Costedoat-Chalumeau N, et al. Relapsing polychondritis: state of the art on clinical practice guidelines. RMD Open. 2018;4(Suppl 1):e000788.
3. Borgia F, Giuffrida R, Guarneri F, Cannavò SP. Relapsing Polychondritis: An Updated Review. Biomedicines. 2018 Aug 2;6(3).
4. Moulis G, Pugnet G, Costedoat-Chalumeau N, Mathian A, Leroux G, Boutémy J, et al. Efficacy and safety of biologics in relapsing polychondritis: a French national multicentre study. Ann Rheum Dis. 2018;77(8):1172–8.
5. Meshkov AD, Novikov PI, Zhilyaev EV, Ilevsky IDJ, Moiseev SV. Tofacitinib in steroid-dependent relapsing polychondritis. Ann Rheum Dis. 2019 Jul;78(7):e72.
6. Michet CJ, McKenna CH, Luthra HS, O’Fallon WM. Relapsing polychondritis. Survival and predictive role of early disease manifestations. Ann Intern Med. 1986 Jan;104(1):74–8.
7. Dion J, Costedoat-Chalumeau N, Sène D, Cohen-Bittan J, Leroux G, Dion C, et al. Relapsing Polychondritis Can Be Characterized by Three Different Clinical Phenotypes: Analysis of a Recent Series of 142 Patients. Arthritis Rheumatol Hoboken NJ. 2016;68(12):2992–3001.
8. Rose E, Ferrada MA, Quinn KA, Goodspeed W, Arnaud L, Sharma A, et al. Physician Global Assessment as a Disease Activity Measure for Relapsing Polychondritis. Arthritis Care Res. 2021 Feb 5;
9. Mathian A, Miyara M, Cohen-Aubart F, Haroche J, Hie M, Pha M, et al. Relapsing polychondritis: A 2016 update on clinical features, diagnostic tools, treatment and biological drug use. Best Pract Res Clin Rheumatol. 2016;30(2):316–33.
10. Tillie-Leblond I, Wallaert B, Leblond D, Salez F, Perez T, Remy-Jardin M, et al. Respiratory involvement in relapsing polychondritis. Clinical, functional, endoscopic, and radiographic evaluations. Medicine (Baltimore). 1998 May;77(3):168–76.
11. Damiani JM, Levine HL. Relapsing polychondritis--report of ten cases. The Laryngoscope. 1979 Jun;89(6 Pt 1):929–46.
12. Oka H, Yamano Y, Shimizu J, Yudoh K, Suzuki N. A large-scale survey of patients with relapsing polychondritis in Japan. Inflamm Regen. 2014;34(3):149–56.
13. Shimizu J, Oka H, Yamano Y, Yudoh K, Suzuki N. Cutaneous manifestations of patients with relapsing polychondritis: an association with extracutaneous complications. Clin Rheumatol. 2016 Mar;35(3):781–3.
14. Hebbar M, Brouillard M, Wattel E, Decoulx M, Hatron PY, Devulder B, et al. Association of myelodysplastic syndrome and relapsing polychondritis: further evidence. Leukemia. 1995 Apr;9(4):731–3.
15. Beck DB, Ferrada MA, Sikora KA, Ombrello AK, Collins JC, Pei W, et al. Somatic Mutations in UBA1 and Severe Adult-Onset Autoinflammatory Disease. N Engl J Med. 2020 Dec;383(27):2628–38.
16. Tsuchida N, Kunishita Y, Uchiyama Y, Kirino Y, Enaka M, Yamaguchi Y, et al. Pathogenic UBA1 variants associated with VEXAS syndrome in Japanese patients with relapsing polychondritis. Ann Rheum Dis. 2021 Mar 31;
17. McAdam LP, O’Hanlan MA, Bluestone R, Pearson CM. Relapsing polychondritis: prospective study of 23 patients and a review of the literature. Medicine (Baltimore). 1976 May;55(3):193–215.
18. Trentham DE, Le CH. Relapsing polychondritis. Ann Intern Med. 1998 Jul;129(2):114–22.
19. Rabuzzi DD. Relapsing polychondritis. Arch Otolaryngol Chic Ill 1960. 1970 Feb;91(2):188–94.
20. Shimizu J, Yamano Y, Yudoh K, Suzuki N. Organ involvement pattern suggests subgroups within relapsing polychondritis: comment on the article by Dion et al. Arthritis Rheumatol Hoboken NJ. 2018;70(1):148–9.
21. Hazra N, Dregan A, Charlton J, Gulliford MC, D’Cruz DP. Incidence and mortality of relapsing polychondritis in the UK: a population-based cohort study. Rheumatol Oxf Engl. 2015 Dec;54(12):2181–7.
22. Lin D-F, Yang W-Q, Zhang P-P, Lv Q, Jin O, Gu J-R. Clinical and prognostic characteristics of 158 cases of relapsing polychondritis in China and review of the literature. Rheumatol Int. 2016 Jul;36(7):1003–9.
23. Mohsenifar Z, Tashkin DP, Carson SA, Bellamy PE. Pulmonary function in patients with relapsing polychondritis. Chest. 1982 Jun;81(6):711–7.
24. Arnaud L, Devilliers H, Peng SL, Mathian A, Costedoat-Chalumeau N, Buckner J, et al. The Relapsing Polychondritis Disease Activity Index: development of a disease activity score for relapsing polychondritis. Autoimmun Rev. 2012 Dec;12(2):204–9.
25. Badireddi S, Siddiqui MF, Boddu NJ. Respiratory failure secondary to relapsing polychondritis. Respir Care. 2014 Sep;59(9):e140-143.
26. Sato T, Yamano Y, Tomaru U, Shimizu Y, Ando H, Okazaki T, et al. Serum level of soluble triggering receptor expressed on myeloid cells-1 as a biomarker of disease activity in relapsing polychondritis. Mod Rheumatol. 2014 Jan;24(1):129–36.
27. Thaiss WM, Nikolaou K, Spengler W, Spira D, Xenitidis T, Henes J, et al. Imaging diagnosis in relapsing polychondritis and correlation with clinical and serological data. Skeletal Radiol. 2016 Mar;45(3):339–46.
28. Stabler T, Piette J-C, Chevalier X, Marini-Portugal A, Kraus VB. Serum cytokine profiles in relapsing polychondritis suggest monocyte/macrophage activation. Arthritis Rheum. 2004 Nov;50(11):3663–7.
29. Wang Y, Zhao Z, Gao D, Wang H, Liao S, Dong C, et al. Additive effect of leflunomide and glucocorticoids compared with glucocorticoids monotherapy in preventing relapse of IgG4-related disease: A randomized clinical trial. Semin Arthritis Rheum. 2020 Dec;50(6):1513–20.
30. Charles P, Perrodeau É, Samson M, Bonnotte B, Néel A, Agard C, et al. Long-Term Rituximab Use to Maintain Remission of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A Randomized Trial. Ann Intern Med. 2020 Aug 4;173(3):179–87.
31. Shirakashi M, Yoshifuji H, Kodama Y, Chiba T, Yamamoto M, Takahashi H, et al. Factors in glucocorticoid regimens associated with treatment response and relapses of IgG4-related disease: a multicentre study. Sci Rep. 2018 Jul 6;8(1):10262.